2014
DOI: 10.1016/j.jmbbm.2014.02.008
|View full text |Cite
|
Sign up to set email alerts
|

Influence of microstructural purity on the bending fatigue behavior of VAR-melted superelastic Nitinol

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
43
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 38 publications
(46 citation statements)
references
References 16 publications
3
43
0
Order By: Relevance
“…Atom probe tomography (APT) was used to measure phase compositions and precipitate size after aging in a non-transforming Pd 30 Ni 20 Ti 38 Zr 8 Al 4 ''hybrid'' alloy prototype. For the isothermal study, samples were aged at 600°C for 0.25, 1, 3, 5, 10, and 100 h. For the isochronal study, samples were aged for 3 h at 500, 530, and 600°C.…”
Section: Experimental Methodsmentioning
confidence: 99%
See 4 more Smart Citations
“…Atom probe tomography (APT) was used to measure phase compositions and precipitate size after aging in a non-transforming Pd 30 Ni 20 Ti 38 Zr 8 Al 4 ''hybrid'' alloy prototype. For the isothermal study, samples were aged at 600°C for 0.25, 1, 3, 5, 10, and 100 h. For the isochronal study, samples were aged for 3 h at 500, 530, and 600°C.…”
Section: Experimental Methodsmentioning
confidence: 99%
“…For automotive applications, use of precious metals such as Pd or Pt may be prohibitive, while the cost-to-benefit ratio may be acceptable in aerospace or medical applications. A cost analysis of stent devices indicated that while replacing a binary NiTi alloy with a low-Ni Pd 30 Ni 20 Ti 46 Al 4 alloy would increase the cost of raw materials by a factor of 3.7; the raw materials make up just a small portion of the device cost to hospitals, resulting in a projected device cost increase of only 8 % [12]. This cost increase might be outweighed by the benefit that a biocompatible PdTi-based device would provide to a severely Ni-hypersensitive patient with no treatment alternative.…”
Section: Design Objectivesmentioning
confidence: 99%
See 3 more Smart Citations